

Table 4. Univariate and multivariate analysis in favorable-risk RCC patients.

Overall Survival	Univariate Cox Regression		Multivariate Cox Regression	
	HR (95%CI)	p-value	HR (95%CI)	p-value
Gender (females vs males)	1.02 (0.71–1.48)	0.899		
Age (≥ 65y vs < 65y)	1.47 (0.94–1.97)	0.341		
Nephrectomy (yes vs no)	0.65 (0.32–1.33)	0.241		
Histology (nccRCC vs ccRCC)	1.28 (0.85–1.92)	0.241		
Sarcomatoid features (yes vs no)	1.60 (0.92–2.79)	0.094		
Lung metastases (yes vs no)	0.97 (0.71–1.33)	0.852		
Bone metastases (yes vs no)	1.03 (0.70–1.50)	0.896		
Liver metastases (yes vs no)	1.92 (1.32–2.81)	<0.001		
Brain metastases (yes vs no)	0.96 (0.47–1.96)	0.911		
Glandular metastases (yes vs no)	0.78 (0.49–1.27)	0.320		
Time from RCC diagnosis to metastasis >36 vs ≤36 months	0.73 (0.54–1.00)	0.059		
Sunitinib vs TKI plus ICI	1.08 (0.69–1.67)	0.741		
Progression-Free Survival				
Progression-Free Survival	Univariate Cox Regression		Multivariate Cox regression	
	HR (95%CI)	p-value	HR (95%CI)	p-value
Gender (females vs males)	1.08 (0.80–1.47)	0.607		
Age (≥65y vs <65y)	1.05 (0.84–1.31)	0.682		
Nephrectomy (yes vs no)	1.73 (0.85–3.50)	0.129		
Histology (nccRCC vs ccRCC)	1.98 (1.40–2.80)	< 0.001	1.85 (1.31–2.62)	< 0.001
Sarcomatoid features (yes vs no)	1.11 (0.63–1.95)	0.711		
Lung metastases (yes vs no)	1.12 (0.86–1.47)	0.410		
Bone metastases (yes vs no)	1.15 (0.85–1.57)	0.837		
Liver metastases (yes vs no)	1.81 (1.30–2.53)	< 0.001	1.58 (1.12–2.22)	< 0.009
Brain metastases (yes vs no)	1.12 (0.65–1.92)	0.688		
Glandular metastases (yes vs no)	0.94 (0.67–1.33)	0.732		
Time from RCC diagnosis to metastasis >36 vs ≤36 months	0.85 (0.65–1.10)	0.220		

Sunitinib vs TKI plus ICI	1.48 (1.12–1.95)	0.006	1.36 (1.02–1.80)	0.037
<p>ccRCC = clear cell Renal Cell Carcinoma; IMDC = International Metastatic RCC Database Consortium; IO = immune-checkpoint inhibitor; nccRCC = non-clear cell Renal Cell Carcinoma; TKI = tyrosine kinase inhibitor</p>				